MCM
ANIP icon

Marathon Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Marathon Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58M Buy
72,590
+2,925
+4% +$228K 1.25% 26
2025
Q4 		$5.5M Sell
69,665
-40
-0.1% -$3.46K 1.18% 27
2025
Q3 		$6.38M Sell
69,705
-2,320
-3% -$189K 1.46% 22
2025
Q2 		$4.7M Buy
72,025
+2,830
+4% +$184K 1.2% 24
2025
Q1 		$4.63M Sell
69,195
-700
-1% -$41.8K 1.23% 26
2024
Q4 		$3.86M Sell
69,895
-150
-0.2% -$8.61K 0.97% 30
2024
Q3 		$4.18M Sell
70,045
-250
-0.4% -$15.3K 1.01% 27
2024
Q2 		$4.48M Sell
70,295
-875
-1% -$56.8K 1.14% 19
2024
Q1 		$4.92M Buy
71,170
+1,350
+2% +$81.5K 1.17% 25
2023
Q4 		$3.85M Sell
69,820
-1,850
-3% -$102K 0.97% 29
2023
Q3 		$4.16M Buy
71,670
+3,025
+4% +$175K 1.05% 28
2023
Q2 		$3.7M Sell
68,645
-16,245
-19% -$720K 0.91% 30
2023
Q1 		$3.37M Buy
84,890
+12,000
+16% +$506K 0.83% 32
2022
Q4 		$2.93M Hold
72,890
– – 0.81% 28
2022
Q3 		$2.34M Sell
72,890
-1,570
-2% -$53.7K 0.67% 35
2022
Q2 		$2.21M Sell
74,460
-550
-0.7% -$15.9K 0.71% 32
2022
Q1 		$2.11M Buy
75,010
+240
+0.3% +$8.95K 0.61% 41
2021
Q4 		$3.44M Buy
74,770
+575
+0.8% +$24.7K 0.81% 31
2021
Q3 		$2.44M Buy
+74,195
New +$2.31M 0.55% 37

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marathon Capital Management's ANIP Position: Q1 2026 in Review

Marathon Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 4.2% in Q1 2026, buying an estimated $228K and bringing the position to 72,590 shares worth $5.58M. The position accounts for 1.25% of the portfolio, ranked #26.

Marathon Capital Management first reported a position in ANIP in Q3 2021 and has held it in 19 quarters since. The position peaked at $6.38M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Marathon Capital Management held 72,590 shares of ANI Pharmaceuticals worth $5.58M as of Q1 2026.
  • Marathon Capital Management bought 2,925 ANI Pharmaceuticals shares in Q1 2026, an estimated $228K.
  • ANI Pharmaceuticals made up 1.25% of Marathon Capital Management's portfolio in Q1 2026, its #26 holding.
  • Marathon Capital Management first reported a position in ANI Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Marathon Capital Management's ANI Pharmaceuticals position peaked at $6.38M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.